Research is the cornerstone of our commitment. We invest heavily in cutting-edge research, partnering with world-renowned experts, and fostering a culture of curiosity and innovation among our staff. Through rigorous scientific inquiry, we aim to unlock the mysteries of these diseases, paving the way for groundbreaking treatments and cures. We are dedicated to translating research findings into tangible benefits for our patients, ensuring that the latest advancements in medical science are accessible to all who need them.
We see a future where life-threatening diseases are conquered, where patients find solace in our unwavering commitment to their well-being, and where our dedication to research leads to breakthroughs that transform healthcare for generations to come. Together, we can make this vision a reality, offering hope, healing, and a brighter future for all those affected by life-threatening diseases.
We are living in a time of enormous scientific innovation and promise for improved human health. Our understanding of biology is expanding enormously alongside increased identification of novel targets and their associated modalities. Still, drug-development costs and timelines continue to rise, and the likelihood of success continues to fall.
We believe the time is right for a true step change in drug development. To make this a reality, holistic transformation is necessary. While there is no silver bullet, drug developers can make a concerted effort to apply and integrate multiple innovations that can transform development.
To transform drug development, this acceleration can be combined with improved quality and compliance, enhanced patient and healthcare-professional experience, better insights and decision making.
The framework Reimagining R&D demands transformation of the traditional approach to drug development to allow medicines to reach patients faster, reduce development costs, and improve insights and decision making. Five pillars form the basis of development excellence:
Patient- and healthcare-professional-centered design thinking, incorporated end-to-end from program and trial design to trial execution, approval, and launch.
Process redesign, both cross-functionally and within R&D groups, that improves speed of development and builds on research insights.
Digital and technology enablement that allows automation of highly repetitive processes alongside generation of new insights and data .
Advanced analytics (including predictive modeling), informed through internal and external data sources, that improves decision-making quality and speed.
Agile ways of working, with a working model optimized for speed and decision making across the portfolio.